Search
Paltusotine
go.drugbank.com/drugs/DB16277ApprovedInvestigational[A274476] Paltusotine was approved by the FDA on September 25, 2025 for the treatment of acromegaly in adults.[L54061]
Ubrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigational[erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years.[A189207] Ubrogepant was approved by Health Canada on November 10, 2022. … Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults.
Human cytomegalovirus immune globulin
go.drugbank.com/drugs/DB13886ApprovedInvestigationalThe seroprevalence of antibodies in adults ranges from 40-100 % with an inverse correlation to socioeconomic status. … During the span of an individual's life, the virus may reactivate, resulting in repeated shedding and spread of the virus.
Inotersen
go.drugbank.com/drugs/DB14713ApprovedInvestigationalIt was FDA approved in October 2018. … Inotersen is a transthyretin-directed antisense oligonucleotide for the treatment of the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults.
Amlexanox
go.drugbank.com/drugs/DB01025ApprovedWithdrawnAmlexanox is an antiallergic drug, clinically effective for atopic diseases, especially allergic asthma and rhinitis. … Recurrent aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect between 5% and 50% of the general population.
Spironolactone
go.drugbank.com/drugs/DB00421ApprovedInvestigational[A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243]
Chloroprocaine
go.drugbank.com/drugs/DB01161ApprovedInvestigationalChloroprocaine is an ester local anesthetic commonly available in its salt form, chloroprocaine hydrochloride. … [A252952] Chloroprocaine can be given as an injection, and is available in formulations with and without methylparaben as a preservative.
Concizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigational[L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors. … [A264883,A264878] In patients with hemophilia A or B - characterized by deficiencies in clotting factors VIII or IX, respectively - the traditional treatment involves replacement of the missing clotting
Brincidofovir
go.drugbank.com/drugs/DB12151ApprovedInvestigationalBrincidofovir is an oral antiviral drug used in the treatment of human smallpox infections. … [L34470] As smallpox has been eradicated, the efficacy of Tembexa was assessed in animals infected with viruses closely related to variola.